Top

Published in:

01-01-2013 | Original Article

Hsp90 and its co-chaperone, Sgt1, as autoantigens in dilated cardiomyopathy

Authors: Lyudmila L. Kapustian, Olga A. Vigontina, Olga T. Rozhko, Dmytro V. Ryabenko, Wojciech Michowski, Wiesława Lesniak, Anna Filipek, Irina V. Kroupskaya, Lyudmila L. Sidorik

Published in: Heart and Vessels | Issue 1/2013

Abstract

Recently, it has been suggested that some heat shock proteins such as Hsp70 and Hsp60 are involved in autoimmune diseases including cardiospecific ones. In this work we focused on the involvement of another well known heat shock protein, Hsp90, and its novel co-chaperone, Sgt1, in dilated cardiomyopathy (DCM). We found that the level of autoantibodies against these two proteins was significantly higher in patients with DCM and ischemic heart disease than in sera of healthy donors. We have also analyzed the expression level and subcellular localization of Hsp90 and Sgt1 in diseased myocardia. Using Western blot we found changes in subcellular localization of Hsp90 in the left ventricle of DCM hearts while the total level of this protein remained unchanged. Regarding the Sgt1 protein, we found an increased level in DCM and no changes in subcellular localization. Taken together, our data suggest that Hsp90 and Sgt1 might be involved in the progression of heart failure and might serve as markers for cardiomyopathies of different origin.

Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB (2006) Contemporary definitions and classification of the cardiomyopathies. An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807–1816PubMedCrossRef

Gill C, Mestril R, Samali A (2002) Losing heart: the role of apoptosis in heart diseases—a novel therapeutic target? FASEB J 16:135–146PubMedCrossRef

Narula J, Haider N, Arbustini E, Chandrashekhar Y (2006) Mechanisms of disease: apoptosis in heart failure—seeing hope in death. Nat Clin Pract 3:681–688

Avrameas S (1991) Natural autoantibodies: from “horror autotoxicus” to “gnothi seauton”. Immunol Today 12:154–159PubMed

Xiao H, Wang M, Du Y, Yuan J, Zhao G, Tu D, Liao Y-H (2011) Agonist-like autoantibodies against calcium channel in patients with dilated cardiomyopathy. Heart Vessels. doi:10.1007/s00380-011-0176-7

Nollen EAA, Morimoto R (2002) Chaperoning signaling pathways: molecular chaperons as stress-sensing “heat shock” proteins. J Cell Sci 115:2809–2816PubMed

Hayes SA, Dice JF (1996) Roles of molecular chaperones in protein degradation. J Cell Biol 132:255–258PubMedCrossRef

Pockley AG, Bulmer J, Hanks BM, Wright BH (1999) Identification of human heat shock protein 60 (Hsp60) and anti-Hsp60 antibodies in the peripheral circulation of normal individuals. Cell Stress Chaperones 4:29–35PubMedCrossRef

Gupta S, Knowlton A (2005) Hsp60, Bax, apoptosis and the heart. J Cell Mol Med 9:51–58PubMedCrossRef

10.

Wu T, Tanguay RM (2006) Antibodies against heat shock proteins in environmental stresses and diseases: friend or foe? Cell Stress Chaperones 11:1–12PubMedCrossRef

11.

Latchman DS (2001) Heat shock proteins and cardiac protection. Cardiovasc Res 51:637–646PubMedCrossRef

12.

Radford N, Fina M, Benjamin IJ, Moreadith RW, Graves KH, Zhao P, Gavya S, Wiethoff A, Sherry AD, Mallow CR, Williams RS (1996) Cardioprotective effects of 70-kDa heat shock protein in transgenic mice. Proc Natl Acad Sci USA 93:2339–2342PubMedCrossRef

13.

Marber MS, Mestril R, Chi SH, Sayen MR, Yellon DM, Dillmann WH (1995) Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest 95:1446–1456PubMedCrossRef

14.

Kovalenko VN, Ryabenko DV, Sidorik LL, Fedorkova OM, Bobyk VI, Kapustian LN (2003) Dilated cardiomyopathy: decreased expression of Hsp70 chaperone in myocardial cytoplasm and mitochondria. Cardiology NIS 1:78–83

15.

Sidorik L, Kyyamova R, Kapustian L, Bobyk V, Rozhko O, Vigontina O, Ryabenko D, Danko I, Maksimchuk O, Filonenko V, Kovalenko VN, Chaschin NA (2005) Molecular chaperon, Hsp60, and cytochrome P450 2E1 co-expression at dilated cardiomyopathy. Cell Biol Intern 29:51–55CrossRef

16.

Kapustian L, Rozhko O, Bobyk V, Kroupska I, Ryabenko D, Khozhaenko Yu, Gurtovyy V, Usenko V, Sidorik L (2008) Changes in the content of molecular chaperon Hsp60 in heart tissue at dilated cardiomyopathy. Biopolym Cell 24:234–240 (English version). http://www.biopolymers.org.ua/

17.

Knowlton AA, Kapadia S, Torre-Amione G, Durand JB, Bies R, Young J, Mann DL (1998) Differential expression of heat shock proteins in normal and failing human hearts. J Mol Cell Cardiol 30:811–818PubMedCrossRef

18.

Latif N, Taylor PM, Khan MA, Yakoub MH, Dunn MJ (1999) The expression of heat shock protein 60 in patients with dilated cardiomyopathy. Basic Res Cardiol 94:112–119PubMedCrossRef

19.

Portig I, Pankuweit S, Maisch B (1997) Antibodies against stress proteins in sera of patients with dilated cardiomyopathy. J Mol Cell Cardiol 29:2245–2251PubMedCrossRef

20.

Patterson C, Cyr D (2002) Welcome to the machine: a cardiologist’s introduction to protein folding and degradation. Circulation 106:2741–2746PubMedCrossRef

21.

Lee Y-T, Jacob J, Michowski W, Nowotny M, Kuznicki J, Chazin WJ (2004) Human Sgt1 binds HSP90 through CHORD-Sgt1 domain and not the tetratricopeptide repeat domain. J Biol Chem 279:16511–16517PubMedCrossRef

22.

Nowotny M, Spiechowicz M, Jastrzhebska B, Filipek A (2003) Calcium-regulated interaction of Sgt1 with S100A6 (Calcyclin) and other S100 proteins. J Biol Chem 278:26923–26928PubMedCrossRef

23.

Matsiota P, Dosquet P, Guilbert B, Avrameas S (1987) Natural autoantibodies in systemic lupus erythematosus. Clin Exp Immunol 69:79–88PubMed

24.

Yonezawa N, Nishida E, Sakai H, Koyasu S, Matsuzaki F, Iida K, Yahara I (1988) Purification and characterization of the 90-kDa heat-shock protein from mammalian tissues. Eur J Biochem 177:1–7PubMedCrossRef

25.

Sidorik LL, Gudzera OI, Dragovoz VA, Tukalo MA, Beresten SF (1991) Immunochemical non-cross-reactivity between eukaryotic and prokaryotic seryl-tRNA synthetases. FEBS Lett 292:76–78PubMedCrossRef

26.

Kapustian LN, Rozhko OT, Bobyk VI, Kroupskaya IV, Sidorik LL (2007) Development and characterization of monospecific anti-Sgt1 antibodies. Biopolym Cell 23:495–500 (English version) .http://www.biopolymers.org.ua/

27.

Laemmli UK (1970) Cleavage of structural proteins during the assembly of bacteriophage T4. Nature 227:680–685PubMedCrossRef

28.

Kadota Y, Shirasu K, Guerois R (2010) NLR sensors meet at the SGT1-HSP90 crossroad. Trends Biochem Sci 35:199–207PubMedCrossRef

29.

Srivastava P (2002) Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2:185–194PubMedCrossRef

30.

Pashov A, Kenderov A, Kyurkchiev S, Kehayov I, Hristova S, Lacroix-Desmazes S, Giltiay N, Varamballi S, Kazatchkine MD, Kaveri SV (2002) Autoantibodies to heat shock protein 90 in the human natural antibody repertoire. Int Immunol 14:453–461PubMedCrossRef

31.

Zabka M, Leśniak W, Prus W, Kuźnicki J, Filipek A (2008) Sgt1 has co-chaperone properties and is up-regulated by heat shock. Biochem Biophys Res Commun 370:179–183PubMedCrossRef

32.

Pandey P, Saleh A, Nakazawa A, Kumar S, Srinivasula SM, Kumar V, Weichselbaum R, Nalin C, Alnemri ES, Kufe D, Kharbanda S (2000) Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 19:4310–4322PubMedCrossRef

33.

Otsuka K, Terasaki F, Shimomura H, Tsukada B, Horii T, Isomura T, Suma H, Shibayama Y, Kitaura Y (2010) Enhanced expression of the ubiquitin–proteasome system in the myocardium from patients with dilated cardiomyopathy referred for left ventriculoplasty: an immunohistochemical study with special reference to oxidative stress. Heart Vessels 25:474–484PubMedCrossRef

34.

Spiechowicz M, Zylicz A, Bieganowski P, Kuznicki J, Filipek A (2007) Hsp70 is a new target of Sgt1—an interaction modulated by S100A6. Biochem Biophys Res Commun 357:1148–1153PubMedCrossRef

35.

Prus W, Filipek A (2011) S100A6 mediates nuclear translocation of Sgt1: a heat shock-regulated protein. Amino Acids 41:781–787PubMedCrossRef

Title: Hsp90 and its co-chaperone, Sgt1, as autoantigens in dilated cardiomyopathy
Authors: Lyudmila L. Kapustian
Olga A. Vigontina
Olga T. Rozhko
Dmytro V. Ryabenko
Wojciech Michowski
Wiesława Lesniak
Anna Filipek
Irina V. Kroupskaya
Lyudmila L. Sidorik
Publication date: 01-01-2013
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 1/2013
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-011-0226-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hsp90 and its co-chaperone, Sgt1, as autoantigens in dilated cardiomyopathy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Clinical characteristics of silent myocardial ischemia diagnosed with adenosine stress 99mTc-tetrofosmin myocardial scintigraphy in Japanese patients with acute cerebral infarction

Assessment of vascular remodeling after the Fontan procedure using a novel very high resolution ultrasound method: arterial wall thinning and venous thickening in late follow-up

Improvement of atrioventricular conduction following catheter ablation of atrioventricular nodal reentry tachycardia in a patient with a prolonged PR interval

Prognostic implications of chronic kidney disease and anemia after percutaneous coronary intervention in acute myocardial infarction patients

Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease

Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy